TNSN01177A1 - Des anticorps pour le recepteur i de facteur de croissance insuline-like. - Google Patents

Des anticorps pour le recepteur i de facteur de croissance insuline-like.

Info

Publication number
TNSN01177A1
TNSN01177A1 TNTNSN01177A TNSN01177A TNSN01177A1 TN SN01177 A1 TNSN01177 A1 TN SN01177A1 TN TNSN01177 A TNTNSN01177 A TN TNSN01177A TN SN01177 A TNSN01177 A TN SN01177A TN SN01177 A1 TNSN01177 A1 TN SN01177A1
Authority
TN
Tunisia
Prior art keywords
antibodies
igf
relates
nucleic acid
methods
Prior art date
Application number
TNTNSN01177A
Other languages
English (en)
Inventor
D Cohen Bruce
Beebe Jean
E Miller Penelope
D Moyer James
R Corvalan Jose
Gallo Michael
Original Assignee
Pfizer
Abgenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22987016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN01177(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer, Abgenix Inc filed Critical Pfizer
Publication of TNSN01177A1 publication Critical patent/TNSN01177A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

LA PRESENTE INVENTION PORTE SUR DES ANTICORPS ET DES PORTIONS DE CES DERNIERS SE LIANT A L’ANTIGENE, QUI SE LIENT SPECIFIQUEMENT AU RECEPTEUR DE FACTEUR I DE CROISSANCE INSULINE-LIKE (IGF-IR) QUI EST DE PREFERENCE L’IGF-IR HUMAIN. L’INVENTION PORTE EGALEMENT SUR DES ANTICORPS ANTI -IGF-IR HUMAIN, Y COMPRIS LES ANTICORPS CHIMERIQUES BISPECIFIQUES, DERIVATISES, A CHAINE UNIQUE OU DES PORTIONS DE PROTEINES DE FUSION. L’INVENTION PORTE EGALEMENT SUR DES MOLECULES D’IMMUNOGLOBULINE ISOLEES A CHAINE LOURDE ET A CHAINE LEGERE DERIVEE DES ANTICORPS ANTI IGF-IR ET DES MOLECULES D’ACIDES NUCLEIQUES CODANT CES MOLECULES. LA PRESENTE INVENTION PORTE EGALEMENT SUR DES METHODES DE FABRICATION D’ANTICORPS ANTI IGF-IR, DES COMPOSITIONS PHARMACEUTIQUES COMPORTANT CES ANTICORPS ET DES METHODES D’UTILISATION DES ANTICORPS ET DES COMPOSITIONS DE CES DERNIERS DANS LE DIAGNOSTIC ET LE TRAITEMENT. LA PRESENTE INVENTION FOURNIT EGALEMENT DES METHODES DE THERAPIE PAR DES GENES AU MOYEN DE MOLECULES D’ACIDES NUCLEIQUES CODANT LES MOLECULES D’IMMUNOGLOBULINE A CHAINE LOURDE ET/OU A CHAINE LEGERE COMPORTANT LES ANTICORPS ANTI IGF-IR- HUMAIN. L’INVENTION SE RAPPORTE EGALEMENT A DES METHODES DE THERAPIE PAR DES GENES ET DES ANIMAUX TRANSGENIQUES COMPORTANT DES MOLECULES D’ACIDES NUCLEIQUES DE LA PRESENTE INVENTION.
TNTNSN01177A 2001-01-05 2001-12-20 Des anticorps pour le recepteur i de facteur de croissance insuline-like. TNSN01177A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25992701P 2001-01-05 2001-01-05

Publications (1)

Publication Number Publication Date
TNSN01177A1 true TNSN01177A1 (fr) 2005-11-10

Family

ID=22987016

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01177A TNSN01177A1 (fr) 2001-01-05 2001-12-20 Des anticorps pour le recepteur i de facteur de croissance insuline-like.

Country Status (51)

Country Link
US (7) US7037498B2 (fr)
EP (4) EP2194067B1 (fr)
JP (4) JP2004531217A (fr)
KR (1) KR100830082B1 (fr)
CN (2) CN1330668C (fr)
AP (1) AP2072A (fr)
AR (1) AR032028A1 (fr)
AT (1) ATE464322T1 (fr)
AU (1) AU2002231368C1 (fr)
BG (3) BG66460B1 (fr)
BR (2) BR0116728A (fr)
CA (1) CA2433800C (fr)
CR (4) CR7045A (fr)
CU (1) CU23447B7 (fr)
CZ (1) CZ301712B6 (fr)
DE (1) DE60141855D1 (fr)
DK (1) DK1399483T3 (fr)
DZ (1) DZ3494A1 (fr)
EA (1) EA012079B3 (fr)
EC (1) ECSP034711A (fr)
EE (2) EE05715B1 (fr)
ES (1) ES2344592T3 (fr)
GE (1) GEP20084484B (fr)
GT (1) GT200100257A (fr)
HK (3) HK1072059A1 (fr)
HN (1) HN2001000283A (fr)
HR (2) HRP20030627A2 (fr)
HU (1) HUP0302525A2 (fr)
IL (2) IL156661A0 (fr)
IS (1) IS2790B (fr)
MA (1) MA26040A1 (fr)
ME (1) ME00502B (fr)
MX (2) MX349009B (fr)
MY (1) MY143465A (fr)
NO (1) NO339789B1 (fr)
NZ (2) NZ527302A (fr)
OA (1) OA12589A (fr)
PA (1) PA8535501A1 (fr)
PE (1) PE20020801A1 (fr)
PL (3) PL228041B1 (fr)
PT (1) PT1399483E (fr)
RS (1) RS51373B (fr)
SG (1) SG138469A1 (fr)
SK (1) SK287954B6 (fr)
SV (1) SV2007000775A (fr)
TN (1) TNSN01177A1 (fr)
TW (1) TWI324609B (fr)
UA (1) UA87804C2 (fr)
UY (2) UY27087A1 (fr)
WO (1) WO2002053596A2 (fr)
ZA (1) ZA200305995B (fr)

Families Citing this family (295)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200305995B (en) 2001-01-05 2004-08-04 Pfizer Antibodies to insulin-like growth factor I receptor.
AU2013204100A1 (en) * 2001-06-26 2013-05-09 Amgen Fremont Inc. Antibodies to OPGL
KR20040023630A (ko) * 2001-06-26 2004-03-18 아브게닉스, 인크. Ｏｐｇｌ에 결합하는 항체
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
DE60312639T2 (de) * 2002-01-18 2007-11-29 Pierre Fabre Médicament Antikörper gegen igf-ir und ihre verwendungen
FR2834991B1 (fr) * 2002-01-18 2004-12-31 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
FR2834990A1 (fr) * 2002-01-18 2003-07-25 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
FR2834900B1 (fr) * 2002-01-18 2005-07-01 Pf Medicament Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications
US6936427B2 (en) * 2002-02-08 2005-08-30 Trellis Bioscience, Inc. Real time detection of intermolecular interaction
JP4699025B2 (ja) 2002-05-15 2011-06-08 サッター・ウエスト・ベイ・ホスピタルズ 核酸様化合物の送達
EP2316921B1 (fr) 2002-05-24 2014-05-14 Merck Sharp & Dohme Corp. Anticorps anti-IGFR humain neutralisant
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
AU2004303792A1 (en) * 2003-12-08 2005-07-07 Immunogen, Inc. Anti-IGF-I receptor antibody
US7456260B2 (en) 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
US20040176291A1 (en) * 2002-09-24 2004-09-09 Elly Nedivi Methods and compositions for soluble CPG15
JP2006517581A (ja) * 2003-02-13 2006-07-27 ファイザー・プロダクツ・インク 抗インスリン様増殖因子ｉ受容体抗体の使用
BRPI0408317A (pt) * 2003-03-14 2006-03-07 Pharmacia Corp anticorpos do receptor de igf-i para o tratamento de cáncer
CA2519113C (fr) 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
CN100378127C (zh) * 2003-04-02 2008-04-02 霍夫曼-拉罗奇有限公司 针对胰岛素样生长因子i受体的抗体及其应用
US7310537B2 (en) * 2003-04-25 2007-12-18 Nokia Corporation Communication on multiple beams between stations
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
ES2338105T3 (es) * 2003-05-14 2010-05-04 Kenta Biotech Ag Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 06 pseudomonas aeruginosa.
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1835975B (zh) * 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
ATE492562T1 (de) * 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin- like growth factor
US20050187175A1 (en) * 2003-09-30 2005-08-25 Elly Nedivi Methods and compositions for CPG15-2
US9011880B2 (en) * 2003-10-21 2015-04-21 Igf Oncology, Llc Compounds and methods for treating cancer
EP1694850B1 (fr) 2003-11-12 2011-06-29 Schering Corporation Systeme de plasmide pour l'expression multigenique
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
KR101201464B1 (ko) 2004-05-05 2012-11-14 메리맥 파마슈티컬즈, 인크. 생물학적 활성을 조정하기 위한 이특이성 결합제
MX2007000610A (es) * 2004-07-16 2007-03-07 Pfizer Prod Inc Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
EP2283831A3 (fr) * 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarqueurs pour la présélection des patients pour la thérapie anti-IGF1R
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
NZ562234A (en) 2005-04-26 2009-09-25 Pfizer P-cadherin antibodies
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
MX2007015476A (es) * 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
JP2008546699A (ja) * 2005-06-15 2008-12-25 シェーリング コーポレイション 抗ｉｇｆ１ｒ抗体処方物
CA2612449A1 (fr) 2005-06-17 2006-12-28 Imclone Systems Incorporated Antagonistes de recepteur pour le traitement de cancer osseux metastatique
WO2007000328A1 (fr) * 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
UA94060C2 (ru) 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
CN100445300C (zh) * 2005-09-30 2008-12-24 李玉新 Glp-1融合蛋白及其制备方法和医药用途
AU2006318580A1 (en) 2005-11-21 2007-05-31 Merck Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
US7939637B2 (en) 2005-12-13 2011-05-10 Medimmune Limited Insulin-like growth factor antibodies and uses thereof
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
DK1973946T3 (da) 2006-01-20 2015-06-22 Cell Signaling Technology Inc Translokation og mutant ros kinase i human ikke-småcellet lungekarcinom
JP5198289B2 (ja) 2006-02-03 2013-05-15 イムクローン・リミテッド・ライアビリティ・カンパニー 前立腺癌の治療用アジュバントとしてのｉｇｆ−ｉｒアンタゴニスト
US7884078B2 (en) * 2006-02-10 2011-02-08 Massachusetts Institute Of Technology CPG15 compounds as insulin receptor and insulin-like growth factor receptor agonists
BRPI0709843A2 (pt) * 2006-03-28 2011-07-26 Biogen Idec Inc anticorpos de anti-igf-1r e usos dos mesmos
EP1998806A1 (fr) * 2006-03-28 2008-12-10 F. Hoffmann-Roche AG Formulation d'anticorps monoclonal humain anti-igf-1r
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP3266867A1 (fr) 2006-04-14 2018-01-10 Cell Signaling Technology, Inc. Défauts de gène et alk kinase mutante dans des tumeurs solides humaines
EP2258700A1 (fr) 2006-05-09 2010-12-08 Pfizer Products Inc. Dérivés d'acides aminés cycloalkyles et compositions pharmaceutiques les contenant
CA2655997A1 (fr) 2006-06-30 2008-01-10 Schering Corporation Biomarqueur igfbp2
WO2008076278A2 (fr) 2006-12-13 2008-06-26 Schering Corporation Procédés de traitements
WO2008079849A2 (fr) * 2006-12-22 2008-07-03 Genentech, Inc. Anticorps liés au récepteur du facteur de croissance semblable à l'insuline
KR20090114449A (ko) * 2007-02-14 2009-11-03 글락소 그룹 리미티드 Ｉｇｆ-ⅰｒ에 대한 항체
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
CN101617228A (zh) * 2007-02-27 2009-12-30 霍夫曼-拉罗奇有限公司 用于评估针对胰岛素样生长因子ⅰ受体的抗体的抑制活性的方法
US20100166747A1 (en) * 2007-03-02 2010-07-01 Beltran Pedro J Methods and compositions for treating tumor diseases
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CA2683559C (fr) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methodes de traitement d'un cancer resistant a des agents therapeutiques anti-erbb
WO2008144345A2 (fr) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarqueurs et procédés pour déterminer la sensibilité de modulateurs de récepteur de facteur de croissance de type 1 semblable à l'insuline
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
AU2008295506A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-IGF-1R antibodies and uses thereof
JP2010538012A (ja) * 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド Ｉｇｆ−１ｒの複数のエピトープに結合する組成物
US20110097318A1 (en) * 2007-08-31 2011-04-28 Amgen Inc. Solid-State Protein Formulation
US8383114B2 (en) * 2007-09-27 2013-02-26 Amgen Inc. Pharmaceutical formulations
ES2576650T3 (es) 2007-10-18 2016-07-08 Cell Signaling Technology, Inc. Translocación y ROS quinasa mutante en el carcinoma pulmonar no microcítico humano
WO2009064838A1 (fr) 2007-11-15 2009-05-22 Amgen, Inc. Préparation aqueuse de protéine de stimulation de l'érythropoïèse stabilisée par des antioxydants pour une administration par voie parentérale
PT2242771E (pt) 2007-12-14 2013-08-29 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
JP5458020B2 (ja) 2007-12-21 2014-04-02 ロシュ グリクアート アクチェンゲゼルシャフト 抗体の安定性試験
JP2011515478A (ja) * 2008-03-25 2011-05-19 シェーリング コーポレイション 結腸直腸がんを処置または予防するための方法
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
JP5674654B2 (ja) 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
PT2376116E (pt) 2008-12-12 2016-02-24 Boehringer Ingelheim Int Anticorpos anti-igf
PT2881402T (pt) 2009-02-12 2017-08-23 Cell Signaling Technology Inc Expressão de ros mutante em cancro de fígado humano
PL3903829T3 (pl) 2009-02-13 2023-08-14 Immunomedics, Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
EP2236139A1 (fr) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Thérapie combinée d'erlotinibe avec un anticorps anti-IGF-1R, qui n'inhibe pas la liaison d'insuline dans le récepteur d'insuline
AR075982A1 (es) 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
WO2010120599A2 (fr) 2009-04-16 2010-10-21 Merck Sharp & Dohme Corp. Compositions et procédés destinés au traitement du cancer
MY153078A (en) * 2009-04-27 2014-12-31 Novartis Ag Compositions and methods for increasing muscle growth
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
DK2798950T4 (da) 2009-07-08 2023-05-15 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
CN102482701B (zh) 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
BR112012009828B8 (pt) 2009-10-26 2022-10-25 Hoffmann La Roche Método para a produção de uma imunoglobulina glicosilada e seu uso
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053779A2 (fr) 2009-10-30 2011-05-05 Bristol-Myers Squibb Company Méthodes pour traiter un cancer chez des patients présentant une résistance à l'inhibiteur d'igf-1r
WO2011068845A1 (fr) 2009-12-02 2011-06-09 Immunomedics, Inc. Combinaison de radioimmunotherapie et conjugues anticorps-medicament pour une meilleure therapie du cancer
WO2011083391A2 (fr) 2010-01-05 2011-07-14 Pfizer Inc. Biomarqueurs pour une thérapie du cancer par un anti-igf-1r
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP2501817B2 (fr) 2010-02-08 2021-04-21 Regeneron Pharmaceuticals, Inc. Souris à chaîne légère commune
WO2011101328A2 (fr) 2010-02-18 2011-08-25 Roche Glycart Ag Traitement au moyen d'un anticorps anti-egfr de la classe igg humanisé et d'un anticorps contre le récepteur du facteur de croissance 1 analogue à l'insuline
EP2571992B1 (fr) * 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Protéines hybrides bispécifiques
SI2575935T2 (sl) 2010-06-07 2023-12-29 Amgen Inc. Naprava za dajanje zdravila
WO2011161119A1 (fr) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Anticorps contre le récepteur du facteur de croissance insulinique i et ses utilisations
SG186451A1 (en) 2010-07-12 2013-01-30 Covx Technologies Ireland Ltd Multifunctional antibody conjugates
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012019132A2 (fr) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Kinase des lymphomes anaplasiques dans le cancer du rein
RU2013113225A (ru) 2010-08-26 2014-10-10 Эббви Инк. Иммуноглобулины с двумя вариабельными доменами и их применение
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
UA114592C2 (uk) * 2010-09-28 2017-07-10 Ноно Інк. Пептид nd2 та спосіб лікування неврологічного захворювання
EP2640750A1 (fr) * 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents et méthodes de traitement de maladies qui sont corrélées à une expression de bcma
CA2820619C (fr) 2010-11-24 2020-01-07 Litron Laboratories, Ltd. Evaluation de mutation genetique in vivo rapide sur la base du gene pig-a
JP2014510265A (ja) 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Ｉｇｆ−１ｒの阻害に関する方法および組成物
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
MX369659B (es) 2011-03-29 2019-11-15 Immunogen Inc Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa.
SG193996A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
AU2012236573B2 (en) 2011-03-31 2016-06-02 Amgen Inc. Vial adapter and system
WO2012145183A2 (fr) 2011-04-19 2012-10-26 Pfizer Inc. Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer
EP2699602B1 (fr) * 2011-04-19 2017-03-01 Merrimack Pharmaceuticals, Inc. Anticorps anti-igf-1r et anti-erbb3 bispécifiques
HUE042822T2 (hu) 2011-04-20 2019-07-29 Amgen Inc Automata befecskendezõ szerkezet
WO2012151199A1 (fr) 2011-05-02 2012-11-08 Immunomedics, Inc. Concentration d'ultrafiltration d'anticorps à allotype sélectionné pour une administration de petit volume
JP6510234B2 (ja) 2011-08-05 2019-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化ユニバーサル軽鎖マウス
CN103857700A (zh) 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体
JP2014533930A (ja) * 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
WO2013045916A1 (fr) 2011-09-26 2013-04-04 Kymab Limited Chaînes légères substituts (cls) chimères comprenant vpreb humain
EP2766497A1 (fr) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Procédés de sélection et de traitement du cancer chez des patients au moyen d'inhibiteurs de l'igf-1r/ir
IL301153B2 (en) 2011-10-14 2024-05-01 Amgen Inc Syringe and assembly method
WO2013060872A1 (fr) * 2011-10-27 2013-05-02 Boehringer Ingelheim International Gmbh Polythérapie anticancéreuse
EA034989B1 (ru) 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
WO2013071056A2 (fr) 2011-11-11 2013-05-16 Duke University Polythérapie médicamenteuse pour le traitement de tumeurs solides
KR101470700B1 (ko) * 2011-11-25 2014-12-12 서울대학교산학협력단 표적 항암제의 내성 극복 방법
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9997847B2 (en) 2011-12-27 2018-06-12 Perfectvision Manufacturing, Inc. Coaxial Connector with grommet biasing for enhanced continuity
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
EP2631653A1 (fr) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification de modulateurs de liaison des propriétés d'anticorps réactifs avec un élément de la famille des récepteurs de l'insuline
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
SI2838998T1 (en) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. EGFR AND ROS1 PRI CRAK
CA2871711A1 (fr) 2012-05-04 2013-11-07 Pfizer Inc. Regimes immunotherapeutiques bases sur des antigenes associes a la prostate et un vaccin
US10519245B2 (en) 2012-06-21 2019-12-31 Sorrento Therapeutics Inc. Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer
US9181343B2 (en) 2012-07-19 2015-11-10 Redwood Bioscience Inc. Antibody specific for CD22 and methods of use thereof
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
RU2650788C2 (ru) 2012-08-07 2018-04-17 Роше Гликарт Аг Композиция, содержащая два антитела, сконструированных так, чтобы они обладали пониженной и повышенной эффекторной функцией
US9315567B2 (en) 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN109200290A (zh) 2012-10-04 2019-01-15 伊缪诺金公司 使用pvdf膜纯化细胞结合剂细胞毒性剂缀合物
UY35110A (es) 2012-11-01 2014-05-30 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
CA3206182A1 (fr) 2012-11-21 2014-05-30 Amgen Inc. Dispositif de livraison de medicament comportant un element d'insertion et un reservoir
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
PT2925745T (pt) 2012-11-29 2018-08-08 Chemocentryx Inc Antagonistas de cxcr7
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
CN105705519A (zh) 2013-03-06 2016-06-22 梅里麦克制药股份有限公司 抗C-MET串联Fc双特异性抗体
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP2968775B1 (fr) 2013-03-15 2019-12-18 Amgen Inc. Boîte à médicament, autoinjecteur et système d'autoinjecteur
JP6336564B2 (ja) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド 薬物カセット、自動注入器、および自動注入器システム
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
IL292270B2 (en) 2013-03-22 2024-04-01 Amgen Inc Injector and assembly method
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
MX370377B (es) 2013-04-29 2019-12-11 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-cd38 y fusiones con interferón alfa-2b atenuado.
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
AU2014280847B2 (en) * 2013-06-13 2019-07-04 Antisense Therapeutics Ltd Combination therapy
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
JP6668241B2 (ja) 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
CA2925723A1 (fr) 2013-10-01 2015-04-09 Kymab Limited Modeles d'animaux et molecules therapeutiques
EP3501575B1 (fr) 2013-10-24 2021-12-01 Amgen Inc. Système de distribution de médicaments équipé d'un dispositif de commande sensible à la température
MX2016005312A (es) 2013-10-24 2016-08-11 Amgen Inc Inyector y metodo de montaje.
EP3094339B1 (fr) 2014-01-12 2019-12-11 IGF Oncology, LLC Protéines de fusion contenant un facteur-1 de croissance de type insuline et un facteur de croissance épidermique et leurs variantes
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
EP3107577B1 (fr) 2014-02-21 2024-03-20 IBC Pharmaceuticals, Inc. Traitement d'une maladie par induction d'une réponse immune à des cellules exprimant le trop-2
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3785749A1 (fr) 2014-05-07 2021-03-03 Amgen Inc. Auto-injecteur doté d'éléments de réduction de choc
WO2015175861A1 (fr) 2014-05-16 2015-11-19 Amgen Inc. Dosage pour la détection de populations de cellules th1 et th2
CN106470717B (zh) 2014-06-03 2020-09-11 安姆根有限公司 药物递送系统和使用方法
EP3160504B1 (fr) 2014-06-24 2020-09-16 Immunomedics, Inc. Thérapie par anti-histone pour nécrose vasculaire dans la glomérulonéphrite sévère
AU2015328370B2 (en) 2014-10-07 2021-08-05 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
EP3943135A3 (fr) 2014-10-14 2022-06-29 Amgen Inc. Dispositif d'injection de médicament avec indicateurs visuels et audibles
UA125637C2 (uk) 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
AU2015349985A1 (en) 2014-11-19 2017-05-25 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3848072A1 (fr) 2014-12-19 2021-07-14 Amgen Inc. Dispositif d'administration de médicament comportant un capteur de proximité
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
CA2976935C (fr) 2015-02-17 2020-03-10 Amgen Inc. Dispositif d'administration de medicament a securisation assistee par depression et/ou retour d'informations
AU2016219772A1 (en) * 2015-02-22 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
JP2018512184A (ja) 2015-02-27 2018-05-17 アムジエン・インコーポレーテツド 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置
WO2016149678A1 (fr) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Animaux non humains qui sélectionnent des régions variables de chaînes légères qui se lient à l'antigène
EP3286224A4 (fr) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolement, détection, diagnostic et/ou caractérisation de cellules cancéreuses trop-2 positives
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN114796500A (zh) 2015-06-25 2022-07-29 免疫医疗公司 组合抗trop-2抗体与微管抑制剂、parp抑制剂使癌症治疗结果显著改善
EP3316885B1 (fr) 2015-07-01 2021-06-23 Immunomedics, Inc. Immunoconjugués d'anticorps sn-38 avec un lieur cl2a
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
US10040840B2 (en) 2015-10-02 2018-08-07 Silver Creek Pharmaceuticals, Inc. Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
WO2017120178A1 (fr) 2016-01-06 2017-07-13 Amgen Inc. Auto-injecteur pourvu d'une électronique de signalisation
KR20180105233A (ko) 2016-02-05 2018-09-27 이뮤노젠 아이엔씨 세포 결합제-세포독성제 접합체를 제조하기 위한 효율적인 방법
BR112018067813A2 (pt) 2016-03-10 2019-01-15 Acceleron Pharma Inc proteínas de ligação ao receptor de activina tipo 2 e usos do mesmo
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (fr) 2016-05-02 2017-11-09 Amgen Inc. Adaptateur de seringue et guide pour remplir un injecteur sur le corps
CA3018426A1 (fr) 2016-05-13 2017-11-16 Amgen Inc. Ensemble manchon de flacon
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (fr) 2016-06-03 2017-12-07 Amgen Inc. Appareils et procédés d'essai au choc destinés aux dispositifs d'administration de médicaments
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (fr) 2016-08-17 2018-02-22 Amgen Inc. Dispositif d'administration de médicament avec détection de positionnement.
SG11201903521XA (en) 2016-10-21 2019-05-30 Amgen Inc Pharmaceutical formulations and methods of making the same
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
CN108084262A (zh) * 2016-11-23 2018-05-29 复旦大学 针对寨卡病毒的全人源单域抗体或抗原结合片段及应用
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
EP3582825A1 (fr) 2017-02-17 2019-12-25 Amgen Inc. Dispositif d'administration de médicament à trajet d'écoulement de fluide stérile et procédé d'assemblage associé
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
EP3592402A1 (fr) 2017-03-07 2020-01-15 Amgen Inc. Insertion d'aiguille par surpression
AU2018230486B2 (en) 2017-03-09 2023-05-11 Amgen Inc. Insertion mechanism for drug delivery device
WO2018170099A1 (fr) 2017-03-14 2018-09-20 Amgen Inc. Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
KR102517342B1 (ko) 2017-03-28 2023-03-31 암겐 인코포레이티드 플런저 로드 및 주사기 조립 시스템 및 방법
WO2018217669A1 (fr) 2017-05-21 2018-11-29 Igf Oncology, Llc Conjugué de facteur de croissance insuline-like - produit chimiothérapeutique pour le traitement du syndrome myélodysplasique
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
EP3641857A1 (fr) 2017-06-22 2020-04-29 Amgen Inc. Réduction des impacts/chocs d'activation d'un dispositif
US11395880B2 (en) 2017-06-23 2022-07-26 Amgen Inc. Electronic drug delivery device
WO2019014014A1 (fr) 2017-07-14 2019-01-17 Amgen Inc. Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
IL271173B2 (en) 2017-07-21 2024-04-01 Amgen Inc Gas permeable sealing element for drug container and methods of assembly
EP3658206A1 (fr) 2017-07-25 2020-06-03 Amgen Inc. Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
WO2019032482A2 (fr) 2017-08-09 2019-02-14 Amgen Inc. Système d'administration de médicament à chambre sous pression hydraulique-pneumatique
WO2019036181A1 (fr) 2017-08-18 2019-02-21 Amgen Inc. Injecteur sur-corps avec patch adhésif stérile
CN111511762A (zh) 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019046600A1 (fr) 2017-08-30 2019-03-07 Amgen Inc. Protéines de liaison du récepteur du facteur de croissance 1 apparenté à l'insuline (igf-1r) et procédés d'utilisation
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
EP3691716B1 (fr) 2017-10-06 2023-11-29 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
EP3694578A1 (fr) 2017-10-09 2020-08-19 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
US11459293B2 (en) * 2017-10-27 2022-10-04 Immunebridge Inc. Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene
EP3703779A1 (fr) 2017-11-03 2020-09-09 Amgen Inc. Systèmes et approches pour stériliser un dispositif d'administration de médicament
EP3706830B1 (fr) 2017-11-06 2024-08-07 Amgen Inc. Dispositif d'administration de médicament avec détection de positionnement et de débit
EP3707075A1 (fr) 2017-11-06 2020-09-16 Amgen Inc. Ensembles de remplissage-finition et procédés associés
JP7247174B2 (ja) 2017-11-10 2023-03-28 アムジエン・インコーポレーテツド 薬物送達デバイスのプランジャ
MA50903A (fr) 2017-11-16 2021-05-12 Amgen Inc Auto-injecteur avec détection de décrochage et de point d'extrémité
CA3079540A1 (fr) 2017-11-16 2019-05-23 Amgen Inc. Mecanisme d'insertion d'aiguille pour dispositif d'administration de medicament
JP7212391B2 (ja) 2017-12-14 2023-01-25 エービーエル バイオ インコーポレイテッド ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
WO2019148444A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps anti-ctla4 et leurs procédés de fabrication et d'utilisation
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
EP3826699A1 (fr) 2018-07-24 2021-06-02 Amgen Inc. Dispositifs d'administration pour l'administration de médicaments
MX2021000748A (es) 2018-07-24 2021-03-26 Amgen Inc Dispositivos de suministro para administrar farmacos.
WO2020023220A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration de médicament hybrides dotés d'une partie de fixation collante à placer sur la peau et procédé de préparation associé
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
US12042642B2 (en) 2018-09-28 2024-07-23 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
TW202027806A (zh) 2018-10-02 2020-08-01 美商安進公司 具有內部力傳遞的用於藥物遞送之注射系統
MX2021003491A (es) 2018-10-05 2021-06-18 Amgen Inc Dispositivo de administracion de farmacos con indicador de dosis.
MX2021004219A (es) 2018-10-15 2021-05-27 Amgen Inc Dispositivo de administracion de farmacos con mecanismo de amortiguacion.
CN112689523A (zh) 2018-10-15 2021-04-20 安进公司 用于药物递送装置的平台组装方法
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
JP7246409B2 (ja) * 2018-12-03 2023-03-27 帝人ファーマ株式会社 抗ｉｇｆ－ｉ受容体ヒト化抗体
MX2021006915A (es) 2018-12-12 2021-08-24 Chemocentryx Inc Inhibidores de cxcr7 para el tratamiento de cancer.
WO2020131697A2 (fr) 2018-12-17 2020-06-25 Revitope Limited Recruteur de cellules immunitaires jumelles
JP7510952B2 (ja) 2019-04-24 2024-07-04 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
JP2022545227A (ja) 2019-08-23 2022-10-26 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4229080A1 (fr) 2020-10-15 2023-08-23 Amgen Inc. Glycanes relatifs non appariés dans des procédés de production d'anticorps
JP2024503933A (ja) 2021-01-27 2024-01-29 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド Ｃｄ１６ａに対する単一ドメイン抗体およびその使用
JP2024513313A (ja) * 2021-03-08 2024-03-25 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション ＣＤ６６ｅポリペプチドに結合する分子
CN112794912B (zh) * 2021-04-14 2021-07-06 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
WO2022239720A1 (fr) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 Anticorps d'affinité de liaison vis-à-vis d'antigènes réduite
WO2022246055A1 (fr) 2021-05-21 2022-11-24 Amgen Inc. Procédé d'optimisation d'une recette de remplissage pour un récipient de médicament
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
MX2024003852A (es) 2021-10-05 2024-05-24 Amgen Inc Unión al receptor fc-gamma y contenido de glucanos.
WO2023143484A1 (fr) * 2022-01-29 2023-08-03 明慧医药（杭州）有限公司 Protéine de liaison à l'antigène et son utilisation
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
CN117079823B (zh) * 2023-10-17 2024-01-02 北京大学第三医院（北京大学第三临床医学院） 早期预测选择性胎儿生长受限发病风险筛查的系统和方法

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US586510A (en) * 1897-07-13 Coal-grading machine
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1319120C (fr) 1985-04-01 1993-06-15 John Henry Kenten Lignee cellulaire myelomateuse transformee et expression d'un gene codant pour un polypeptide d'eucaryote a l'aide de cette lignee
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US4968516A (en) * 1989-07-24 1990-11-06 Thompson Neal W Method and apparatus for cooking foodstuffs using auxiliary steam
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
CA2109602C (fr) 1990-07-10 2002-10-01 Gregory P. Winter Methodes de production de membres de paires de liaison specifiques
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
CA2090473A1 (fr) 1990-08-29 1992-03-01 Robert M. Kay Recombinaison homologue dans des cellules mammaliennes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
WO1992015677A1 (fr) 1991-03-01 1992-09-17 Protein Engineering Corporation Procede de developpement de mini-proteines de liaison
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
CZ283601B6 (cs) 1991-04-19 1998-05-13 Subburaman Mohan Inzulinu podobný růstový faktor vázající protein odvozený z lidské kosti
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (fr) 1991-08-20 1993-03-04 Genpharm International, Inc. Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
CA2119930C (fr) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production d'anticorps chimeres - demarche combinatoire
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
EP1514934B1 (fr) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Protéine de liaison biosynthétique pour marqueur de cancer
ATE208374T1 (de) 1992-02-18 2001-11-15 Otsuka Kagaku Kk Beta-laktam und cepham verbindungen und ihre herstellung
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
IT1270882B (it) * 1993-10-05 1997-05-13 Isagro Srl Oligopeptidi ad attivita' fungicida
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
JPH08140528A (ja) 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
MX9708026A (es) 1995-04-20 1997-11-29 Pfizer Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos.
WO1996033266A1 (fr) 1995-04-21 1996-10-24 Cell Genesys, Inc. Creation d'importantes deletions d'adn genomique
CA2761116A1 (fr) * 1995-04-27 1996-10-31 Amgen Fremont Inc. Anticorps humains derives d'une xenosouris immunisee
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
JP2000500654A (ja) * 1995-11-14 2000-01-25 トーマス・ジェファーソン・ユニバーシティ 可溶性ｉｇｆ−１受容体による腫瘍成長に対する誘導耐性
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
CA2244897C (fr) 1996-03-05 2006-04-11 Zeneca Limited Derives de 4-anilinoquinazoline
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
IL118626A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
EP0818442A3 (fr) 1996-07-12 1998-12-30 Pfizer Inc. Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6207669B1 (en) 1996-07-13 2001-03-27 Glaxo Wellcome Inc. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
ATE217315T1 (de) 1996-07-18 2002-05-15 Pfizer Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren
SK21499A3 (en) 1996-08-23 2000-05-16 Pfizer Arylsulfonylamino hydroxamic acid derivatives
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
JP3338064B2 (ja) 1997-01-06 2002-10-28 ファイザー・インク 環状スルホン誘導体
IL131042A0 (en) 1997-02-03 2001-01-28 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ATE292623T1 (de) 1997-05-07 2005-04-15 Sugen Inc 2-indolinonderivate als modulatoren der proteinkinase-ativität
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
IL134300A (en) 1997-08-08 2004-07-25 Pfizer Prod Inc Derivatives of aryloxyacrylylsulfonaminoaminoxamic acid derivatives, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of arthritis, cancer and other diseases characterized by the activity of metalloproteinase-13 of matrix
EP1005470B1 (fr) 1997-08-22 2007-08-01 AstraZeneca AB Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese
WO1999016755A1 (fr) 1997-09-26 1999-04-08 Merck & Co., Inc. Nouveaux inhibiteurs de l'angiogenese
EP1028964A1 (fr) 1997-11-11 2000-08-23 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
CA2322749A1 (fr) 1998-03-03 1999-09-10 Abgenix, Inc. Molecules fixatrices cd147 utilisees comme agents therapeutiques
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6395734B1 (en) 1998-05-29 2002-05-28 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US7173005B2 (en) * 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
ES2213985T3 (es) 1998-11-05 2004-09-01 Pfizer Products Inc. Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico.
AU772676B2 (en) 1998-12-23 2004-05-06 Amgen Fremont Inc. Human monoclonal antibodies to CTLA-4
WO2000050067A1 (fr) 1999-02-26 2000-08-31 Saltech I Göteborg Ab Procede et composition pour la regulation de la production hepatique et extra hepatique du facteur de croissance insulinoide 1
TR200603997T1 (tr) 1999-03-25 2010-01-21 Abbott Gmbh & Co. Kg Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
JP4224894B2 (ja) * 1999-06-04 2009-02-18 チッソ株式会社 複合強化ポリオレフィン樹脂組成物の製造方法及びその製造装置
US7329745B2 (en) * 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
ZA200305995B (en) 2001-01-05 2004-08-04 Pfizer Antibodies to insulin-like growth factor I receptor.
KR20040023630A (ko) * 2001-06-26 2004-03-18 아브게닉스, 인크. Ｏｐｇｌ에 결합하는 항체
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
CN1835975B (zh) * 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
PT2177537E (pt) 2004-01-09 2011-12-13 Pfizer Anticorpos contra madcam
US9672526B2 (en) 2012-03-13 2017-06-06 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
EP2796468A2 (fr) 2014-10-29
EE200300318A (et) 2003-10-15
EE05715B1 (et) 2014-06-16
NO339789B1 (no) 2017-01-30
PL228041B1 (pl) 2018-02-28
SK287954B6 (sk) 2012-07-03
NZ527302A (en) 2006-10-27
PL407889A1 (pl) 2014-10-13
PT1399483E (pt) 2010-07-20
EP1399483B1 (fr) 2010-04-14
CN1330668C (zh) 2007-08-08
US20140120089A1 (en) 2014-05-01
JP6166243B2 (ja) 2017-07-19
AP2072A (en) 2009-12-10
ZA200305995B (en) 2004-08-04
PL224873B1 (pl) 2017-02-28
BR0116728A (pt) 2005-04-12
CR10786A (es) 2009-06-04
JP5697862B2 (ja) 2015-04-08
KR20040030481A (ko) 2004-04-09
ATE464322T1 (de) 2010-04-15
CU23447B7 (es) 2009-10-16
US7982024B2 (en) 2011-07-19
SG138469A1 (en) 2008-01-28
SV2007000775A (es) 2007-03-15
EA012079B3 (ru) 2018-07-31
HK1098162A1 (en) 2007-07-13
CR20140001A (es) 2014-02-05
RS51373B (sr) 2011-02-28
SK9932003A3 (en) 2004-06-08
US9234041B2 (en) 2016-01-12
JP2009108055A (ja) 2009-05-21
MX337162B (es) 2016-02-15
BG66460B1 (bg) 2014-10-31
EP2194067A2 (fr) 2010-06-09
US7700742B2 (en) 2010-04-20
EE201300037A (et) 2014-04-15
HRP20030627A2 (en) 2005-06-30
GEP20084484B (en) 2008-09-25
US20050281812A1 (en) 2005-12-22
CZ20032131A3 (cs) 2004-01-14
CR7045A (es) 2005-09-02
ECSP034711A (es) 2003-10-28
US7815907B2 (en) 2010-10-19
EA200300766A1 (ru) 2004-06-24
IL156661A0 (en) 2004-01-04
MA26040A1 (fr) 2004-04-01
MXPA03006034A (es) 2005-07-01
UY35948A (es) 2016-08-31
JP2015057428A (ja) 2015-03-26
ME00502B (me) 2011-10-10
US20160096894A1 (en) 2016-04-07
JP4456166B2 (ja) 2010-04-28
DZ3494A1 (fr) 2002-07-11
PL413188A1 (pl) 2016-01-18
CZ301712B6 (cs) 2010-06-02
CN1854157A (zh) 2006-11-01
NO20033074D0 (no) 2003-07-04
BG108037A (bg) 2005-04-30
ES2344592T3 (es) 2010-09-01
UY27087A1 (es) 2002-06-20
US20100255538A1 (en) 2010-10-07
YU54203A (en) 2006-03-03
EE05724B1 (et) 2014-10-15
WO2002053596A2 (fr) 2002-07-11
WO2002053596A3 (fr) 2004-01-08
US7037498B2 (en) 2006-05-02
KR100830082B1 (ko) 2008-05-20
CR10134A (es) 2010-09-14
CA2433800A1 (fr) 2002-07-11
AP2001002365A0 (en) 2001-12-31
IS6866A (is) 2003-07-04
JP2004531217A (ja) 2004-10-14
EP2275446A3 (fr) 2012-08-15
EP1399483A2 (fr) 2004-03-24
HUP0302525A2 (hu) 2003-10-28
PL366340A1 (en) 2005-01-24
CN1564829A (zh) 2005-01-12
NZ569856A (en) 2010-03-26
DK1399483T3 (da) 2010-08-02
BG111652A (en) 2014-03-31
CA2433800C (fr) 2016-09-13
EP2194067B1 (fr) 2017-12-06
IL156661A (en) 2008-11-26
US8642037B2 (en) 2014-02-04
HK1072059A1 (en) 2005-08-12
MX349009B (es) 2017-07-06
BG112197A (bg) 2016-05-31
BRPI0116728B1 (pt) 2018-10-30
NO20033074L (no) 2003-07-04
OA12589A (en) 2006-06-08
AU2002231368B2 (en) 2006-11-23
EA012079B1 (ru) 2009-08-28
EP2275446A2 (fr) 2011-01-19
PL217921B1 (pl) 2014-09-30
AR032028A1 (es) 2003-10-22
UA87804C2 (ru) 2009-08-25
CN1854157B (zh) 2013-01-02
GT200100257A (es) 2002-09-02
HRP20130659A2 (hr) 2013-09-30
AU2002231368C1 (en) 2018-08-16
US20040086503A1 (en) 2004-05-06
JP2009297037A (ja) 2009-12-24
PA8535501A1 (es) 2003-07-28
TWI324609B (en) 2010-05-11
MY143465A (en) 2011-05-13
DE60141855D1 (de) 2010-05-27
HK1203521A1 (en) 2015-10-30
US20120005767A1 (en) 2012-01-05
US20050244408A1 (en) 2005-11-03
HN2001000283A (es) 2002-05-09
IS2790B (is) 2012-06-15
EP2194067A3 (fr) 2012-08-15
PE20020801A1 (es) 2002-09-06

Similar Documents

Publication Publication Date Title
TNSN01177A1 (fr) Des anticorps pour le recepteur i de facteur de croissance insuline-like.
JP6104295B2 (ja) Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
Preud'homme et al. Structural and functional properties of membrane and secreted IgD
MA31246B1 (fr) Anticorps antagoniste d&#39;ox40, et leur utilisation dans le traitement de maladies inflammatoires et auto-immunes
AR047372A1 (es) Anticuerpos contra madcam
ATE435239T1 (de) Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
NO973447D0 (no) Monoklonale antistoffer som er spesifikke for forskjellige epitoper i human-gp 39, og fremgangsmåter for deres anvendelse i diagnose og terapi
CA2366455C (fr) Immuno-adsorbants pour le traitement de la septicemie
US7459158B2 (en) Immunogenic polypeptides for inducing anti-self IgE responses
CA2247804A1 (fr) Compositions de vaccins et methodes utiles pour induire une protection immunitaire contre les peptides arthritogenes impliques dans la pathogenese de la polyarthrite rhumatoide
SK19398A3 (en) Allergen-xcd32 fusion proteins
WO2002059154A3 (fr) Utilisation de souris transgenique pour isoler efficacement de nouveaux anticorps monoclonaux humains a activite de neutralisation de souches primaires du vih-1 et nouveaux anticorps de neutralisation du vih-1
AU2001240982B2 (en) Method for diagnosing efficacy of xenotypic antibody therapy
RU2214279C2 (ru) Усовершенствованные вакцины
EP1621209A2 (fr) Vaccins qui se basent sur des domaines de peptides originaires d&#39;immunoglobuline E
AU2006203074A1 (en) Method for diagnosing efficacy of xenotypic antibody therapy